| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
AstraZeneca PLC (XETRA: ZEG)
ZEG Technical Analysis
4
| As on 26th Sep 2025 ZEG STOCK Price closed @ 126.35 and we RECOMMEND Sell for LONG-TERM with Stoploss of 139.75 & Strong Sell for SHORT-TERM with Stoploss of 143.49 we also expect STOCK to react on Following IMPORTANT LEVELS. |
ZEGSTOCK Price
| Open | 124.15 | Change | Price | % |
| High | 126.50 | 1 Day | 0.75 | 0.60 |
| Low | 124.15 | 1 Week | -5.30 | -4.03 |
| Close | 126.35 | 1 Month | -7.95 | -5.92 |
| Volume | 11251 | 1 Year | -5.35 | -4.06 |
| 52 Week High 157.85 | 52 Week Low 111.75 | ||||
XETRA Germany Most Active Stocks
| LHAR | 2.05 | -20.23% |
| BBVA | 5.00 | -2.72% |
| BBVA | 5.00 | -2.72% |
| BBVA | 5.00 | -2.72% |
| BVBA | 0.02 | -60.00% |
| SNH | 0.16 | 6.67% |
| SNH | 0.16 | 6.67% |
| SNH | 0.16 | 6.67% |
| AMMN | 8500.00 | 1440578.00% |
| PHIA | 31.36 | 1.92% |
XETRA Germany Top Gainers Stocks
XETRA Germany Top Losers Stocks
| ZEG Daily Charts |
ZEG Intraday Charts |
Whats New @ Bazaartrend |
ZEG Free Analysis |
|
|
ZEG Important Levels Intraday
| RESISTANCE | 130.88 |
| RESISTANCE | 129.43 |
| RESISTANCE | 128.53 |
| RESISTANCE | 127.63 |
| SUPPORT | 125.07 |
| SUPPORT | 124.17 |
| SUPPORT | 123.27 |
| SUPPORT | 121.82 |
ZEG Forecast September 2025
| 4th UP Forecast | 144.46 |
| 3rd UP Forecast | 138.65 |
| 2nd UP Forecast | 135.06 |
| 1st UP Forecast | 131.47 |
| 1st DOWN Forecast | 121.23 |
| 2nd DOWN Forecast | 117.64 |
| 3rd DOWN Forecast | 114.05 |
| 4th DOWN Forecast | 108.24 |
ZEG Weekly Forecast
| 4th UP Forecast | 153.33 |
| 3rd UP Forecast | 144.68 |
| 2nd UP Forecast | 139.33 |
| 1st UP Forecast | 133.98 |
| 1st DOWN Forecast | 118.72 |
| 2nd DOWN Forecast | 113.37 |
| 3rd DOWN Forecast | 108.02 |
| 4th DOWN Forecast | 99.37 |
ZEG Forecast2025
| 4th UP Forecast | 217.3 |
| 3rd UP Forecast | 188.13 |
| 2nd UP Forecast | 170.1 |
| 1st UP Forecast | 152.07 |
| 1st DOWN Forecast | 100.63 |
| 2nd DOWN Forecast | 82.6 |
| 3rd DOWN Forecast | 64.57 |
| 4th DOWN Forecast | 35.4 |
AstraZeneca PLC ( XETRA Germany Symbol : ZEG )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
ZEG Business Profile
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom. Address: 1 Francis Crick Avenue, Cambridge, United Kingdom, CB2 0AA
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service